Hospital

Sara Wettergreen, assistant professor in the department of Clinical Pharmacy, and Department of Family Medicine, at Skaggs School of Pharmacy and Pharmaceutical Sciences, on burnout and mental health concerns among pharmacy technicians

Symtuza, a 4-drug combination of darunavir (DRV), a HIV-1 protease inhibitor; cobicistat (COBI), a CYP3A inhibitor; and emtricitabine (FTC) and tenofovir alafenamide (TAF), both HIV-1 nucleoside analog reverse transcriptase inhibitors, is indicated as a complete regimen for the treatment of HIV-1 infection in patients who weigh at least 40 kg.

Dong Xu, PhD, MS, curators' distinguished professor at the University of Missouri College of Engineering, discusses how artificial intelligence is being used to develop new drug therapies for medical treatments targeting cancers and other diseases.

US providers report substantial disruptions in vital supplies of saline injections, prefilled syringes.

Byron Yoshino, PharmD, CEO of Pharmacare Hawaii, discusses the rapidly growing home infusion space within Pharmacare Hawaii’s network of pharmacies.

The vaccine is also credited with saving more than $30 billion in health care costs and more than $40 billion in lost productivity.

Murray Aitken, executive director of IQVIA Institute for Human Data Science, discusses whether patient out of pocket costs rose in 2021, and what the implications may be for the health care system and for patients in 2022.

Prezista is an protease inhibitor indicated for the treatment of HIV-1 infection in patients aged 3 years and older.

Health systems should review HHS’ action plan and determine how to leverage cost savings to help eradicate HCV.

Murray Aitken, executive director of IQVIA Institute for Human Data Science, discusses the implications of the increase in spending on medicines in the United States in 2021.

There is greater than a 98% probability that BI 1015550 was superior to placebo in slowing down the worsening of lung function in individuals with idiopathic pulmonary fibrosis.

They play an indispensable role in the vaccination and management of complex regimens.

Investigators suggested a new test method for the infection with ESAT6/CFP10 and to monitor the disease development and treatment with Ag85B.

Ibalizumab-uiyk (Trogarzo, Theratechnologies) is an injectable CD4-directed post-attachment HIV-1 inhibitor for the treatment of HIV type 1 infection in heavily treatment-experienced adults.

Watch for alopecia, arthralgia, diarrhea, fatigue, nausea, pyrexia, rash, and vomiting, among others.

The analysis, results of which are published in The Lancer Psychiatry, also identifies genetic markers that seem to influence how quickly the body eliminates the medication from its system.

Pharmacists can resolve medication-related problems through face-to-face consultations with patients.

The use of certain drugs, such as statins, may lead to rhabdomyolysis.

Agnieszka Sekula and Prash Puspanathan, MD, co-founders of Enosis Therapeutics, discuss the impact of therapeutic environment on the pharmaceutical effects of psychedelics.

The organizations emphasized the need to better understanding the patient experience for those with recurrent CDI.

Xofigo is indicated for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic disease.

The measures will also affect workers across all areas of the hospital, including dietitians, information technology, nurses, and physicians.

Study results also show a 50% increase in the precancerous condition, Barrett esophagus, between 2012 and 2019, in the same population.

Be aware of products containing gluten, nonsteroidal anti-inflammatory drugs, and olmesartan.

Specialty pharmacy is deeply engaged in providing treatment for conditions that are at high risk for mental health challenges.

Trametinib (Mekinist) is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.

Latest results of the phase 3 IKEMA trial demonstrate the longest median progression-free survival on a proteasome inhibitor backbone in this population, Sanofi says.

The study marks the first time an albuterol/budesonide fixed-dose combination rescue medication has reduced severe exacerbations, the company said.